Anastasia Parafestas is an Equity Research Associate at Jefferies, where she specializes in biotechnology sector analysis and provides research on leading pharma and biotech companies such as Pfizer. She leverages a strong financial analytical skillset to contribute to in-depth modeling and sector insights, supporting coverage of major players in the industry as part of the healthcare research team. Parafestas began her career at Credit Suisse Securities (USA) before joining Jefferies in 2023, and she holds an undergraduate degree from Duke University. Her credentials include substantial buy-side and sell-side research experience, although specific securities licenses and formal third-party performance rankings have not been publicly disclosed.
Anastasia Parafestas asked if there was any perceived risk to the STELLAR-303 trial's approval, citing public apprehension from Vinay regarding Cabometyx's usefulness.
Michael Morrissey, President and CEO, declined to comment on the specific query.
Fintool can predict 
EXEL's earnings beat/miss a week before the call
Anastasia Parafestas asked about any potential risks to the Stellar-303 trial approval, specifically referencing public apprehension about Cabometyx's usefulness.
Michael Morrissey, President and CEO, declined to comment on the specific reference.
Fintool can write a report on EXEL's next earnings in your company's style and formatting
Anastasia Parafestas, on for Akash Tewari, asked how much of the 2025 financial guidance is attributable to the potential NET indication and what the growth trajectory might look like.
Chief Financial Officer Christopher Senner provided a direct response, stating that the potential revenue from the NET indication has not been included in the current 2025 guidance. He clarified that the company will provide updated guidance at a future date, after the drug is approved and they have clarity on the final label.
Fintool can auto-update your Excel models when EXEL reports
Anastasia Parafestas from Jefferies inquired about Alkermes's confidence that elixorexant (ALKS2680) can fully explore its exposure-response range and differentiate on efficacy versus competitors, given potential efficacy limitations seen in other programs.
Richard Pops, Chairman & CEO, responded that Alkermes has always viewed a range of doses as a competitive advantage. He emphasized that the program's ability to dose across a wide range is a key feature and expressed satisfaction with the dose range selected for the VIBRANCE-one study in narcolepsy type 1.
Fintool can predict 
ALKS's earnings beat/miss a week before the call